Track 09 of 9
Clinical Neuroscience & AI
Digital biomarkers, seizure detection and imaging AI.
Artificial intelligence and brain-computer interfaces are moving from prototype to clinic. GCNN 2027 will showcase Neuralink and Synchron BCI early-feasibility outcomes for paralysis and ALS communication, speech-decoding cortical implants, and the regulatory pathway emerging at the FDA. AI-augmented imaging — large vessel occlusion triage (Viz.ai, RapidAI), automated MS lesion segmentation, hippocampal volumetry for AD, and foundation models for radiology — will be examined alongside seizure-forecasting wearables, smartphone-based cognitive and motor digital biomarkers, and the data, privacy and equity questions raised by ambient AI in the neurology clinic.
Focus areas
- Brain-computer interfaces: Neuralink, Synchron, BrainGate clinical readouts
- Speech and motor decoding cortical implants for paralysis and ALS
- AI stroke triage: Viz.ai, RapidAI and door-to-puncture impact
- Foundation models for neuroimaging: MS, AD, glioma segmentation
- Wearable seizure forecasting and ambulatory EEG analytics
- Digital biomarkers: smartphone gait, speech, cognition in PD and AD
- Ambient AI scribes and equitable deployment in neurology clinics